These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25864560)

  • 1. Sanofi’s successful Phase 3 trials may lead to first-ever dengue vaccine in 2015.
    Hum Vaccin Immunother; 2014; 10(12):3427. PubMed ID: 25864560
    [No Abstract]   [Full Text] [Related]  

  • 2. Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015¹. Safety of CYD-TDV dengue vaccine.
    Wkly Epidemiol Rec; 2015 Aug; 90(34):421-3. PubMed ID: 26298882
    [No Abstract]   [Full Text] [Related]  

  • 3. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
    Aguiar M; Stollenwerk N; Halstead SB
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
    Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
    J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine.
    Coudeville L; Baurin N; L'Azou M; Guy B
    Vaccine; 2016 Dec; 34(50):6426-6435. PubMed ID: 27601343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
    Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
    Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sanofi's dengue vaccine first to complete phase 3.
    Sinha G
    Nat Biotechnol; 2014 Jul; 32(7):605-6. PubMed ID: 25004214
    [No Abstract]   [Full Text] [Related]  

  • 8. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies.
    Coudeville L; Baurin N; Vergu E
    Vaccine; 2016 Dec; 34(50):6417-6425. PubMed ID: 26614588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sanofi's dengue vaccine rounds final corner.
    Mullard A
    Nat Rev Drug Discov; 2014 Nov; 13(11):801-2. PubMed ID: 25359368
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccination Against Dengue: Challenges and Current Developments.
    Guy B; Lang J; Saville M; Jackson N
    Annu Rev Med; 2016; 67():387-404. PubMed ID: 26515983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine.
    Wilder-Smith A; Massad E
    Expert Rev Vaccines; 2016; 15(4):437-41. PubMed ID: 26775653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sanofi Pasteur shows efficacy of its dengue vaccine in phase 3.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1427. PubMed ID: 25264688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trolleyology and the Dengue Vaccine Dilemma.
    Rosenbaum L
    N Engl J Med; 2018 Jul; 379(4):305-307. PubMed ID: 29898371
    [No Abstract]   [Full Text] [Related]  

  • 15. Dengue surveillance in preparation for field vaccine trials.
    Letson GW
    J Clin Virol; 2009 Oct; 46 Suppl 2():S10-2. PubMed ID: 19800559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine.
    Precioso AR; Palacios R; Thomé B; Mondini G; Braga P; Kalil J
    Vaccine; 2015 Dec; 33(50):7121-5. PubMed ID: 26458796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in reducing dengue burden; diagnostics, control measures and vaccines.
    Lam SK
    Expert Rev Vaccines; 2013 Sep; 12(9):995-1010. PubMed ID: 24053394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tropical diseases. Dengue vaccine trial poses public health quandary.
    Normile D
    Science; 2014 Jul; 345(6195):367-8. PubMed ID: 25061184
    [No Abstract]   [Full Text] [Related]  

  • 19. Outlook for a dengue vaccine.
    Norrby R
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():92-4. PubMed ID: 24438016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
    Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
    Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.